The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
<h4>Background</h4>Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression after trastuzumab trea...
Main Authors: | Angelo Gámez-Pozo, Ramón M Pérez Carrión, Luis Manso, Carmen Crespo, Cesar Mendiola, Rocío López-Vacas, Julia Berges-Soria, Isabel Álvarez López, Mireia Margeli, Juan L Bayo Calero, Xavier González Farre, Ana Santaballa, Eva M Ciruelos, Ruth Afonso, Juan Lao, Gustavo Catalán, José V Álvarez Gallego, José Miramón López, Francisco J Salvador Bofill, Manuel Ruiz Borrego, Enrique Espinosa, Juan A Fresno Vara, Pilar Zamora |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0109611 |
Similar Items
-
Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
by: M. Calamac, et al.
Published: (2021-04-01) -
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
by: María del Mar Noblejas-López, et al.
Published: (2021-03-01) -
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
by: Volkmar Müller, et al.
Published: (2018-03-01) -
Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01) -
Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
by: Yu Ishimine, et al.
Published: (2015-01-01)